Results 171 to 180 of about 27,147 (278)

Changes in peristalsis following per oral endoscopic myotomy in common esophageal motility disorders. [PDF]

Surg Endosc
Vyas S, Ward MA, Buckmaster B, Aladegbami B, Wang C, Ogola GO, Leeds SG.   +6 more
europepmc   +1 more source

RNA‐Binding Proteins and Ferroptosis in Cancer: Mechanism and Therapeutic Implications

MedComm – Oncology, Volume 5, Issue 1, March 2026.
Ferroptosis critically influences cancer cell fate and represents a promising therapeutic strategy. Emerging evidence identifies RNA‐binding proteins (RBPs) as key post‐transcriptional regulators of ferroptosis. The figure summarizes ferroptosis‐related RBPs across cancers: blue RBPs act as tumor suppressors by promoting ferroptosis, whereas red RBPs ...
Linlin Chang, Bin Lu, Haotian Shang, Wanjing Ding, Chunhua Wei, Xiaotian Qi, Pengxing He   +6 more
wiley   +1 more source

Spectrum of Esophageal Motility Disorders on High-Resolution Manometry in Patients With Non-obstructive Dysphagia. [PDF]

Cureus
Kushwaha DS, Banerjee A.
europepmc   +1 more source

Relationship Between Esophageal Motility Disorders and Autonomic Nervous System in Diabetic Patients: Pilot North African Study. [PDF]

Am J Mens Health, 2022
Syrine G, Mariem MK, Hend K, Imed L.
europepmc   +1 more source

Aging‐Derived Alterations in Genomic, Immune, and Metabolic Networks: Implications for Cancer Development and Therapy

MedComm – Oncology, Volume 5, Issue 1, March 2026.
Ageing acts as a double‐edged sword in cancer. In the elderly, open chromatin, immunosenescence, and chronic inflammation drive SASP (IL‐6, MMPs), MDSC accumulation and T‐cell suppression, fostering tumor‐promoting microenvironments and limited therapeutic benefit.
Qi Wang, Xue Sun, Xinhao Han, Xingda Zhang, Wenzheng Wang, Hongbin Wang, He Ren, Lina Gu   +7 more
wiley   +1 more source

Comparing peroral endoscopic myotomy and laparoscopic Heller myotomy for esophageal motility disorders: Nationwide cohort study. [PDF]

Endosc Int Open
Shiratori Y, Sharma N, Kodilinye SM, Barberan Parraga C, Meribout S, Tokayer A, Hutfless S, Kalloo A.   +7 more
europepmc   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

British Journal of Pharmacology, Volume 183, Issue 6, Page 1271-1287, March 2026.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

[Chicago Classification ver. 4.0: An Overview of Esophageal Motility Disorders on High-resolution Manometry]. [PDF]

Korean J Gastroenterol, 2022
Lee TH.
europepmc   +1 more source

Real‐world benefits and tolerability of trofinetide for the treatment of Rett syndrome: The LOTUS study

Developmental Medicine &Child Neurology, Volume 68, Issue 3, Page 407-417, March 2026.
This original article is commented on by Kaufmann on pages 308–309 of this issue. Plain language summary: https://onlinelibrary.wiley.com/doi/10.1111/dmcn.70051 Abstract Aim To describe the real‐world effects of trofinetide in individuals with Rett syndrome (RTT) using the 18‐month follow‐up analysis of the LOTUS study.
Louise Cosand, Haya Mayman, Jenny Downs, Victor Abler   +3 more
wiley   +1 more source